[Clinical use of "Pentrex" in urological field].
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to S Tsuchida.
Explore the source record for details and available documents.
Two truncated mRNAs, in contrast to the full length of mRNA associated with the glycophorin A gene (GpA-TI, GpA-TII), were isolated from erythroid cells cultured by the selective two-phase liquid culture system for erythroid progenitors in peripheral blood from a normal individual. The GpA-TI mRNAs displayed a direct transition from exon I to exon III, so that the deletion of exon II resulted in the deletion of 33 amino acids encoded by this exon. Furthermore, the GpA-TII showed two direct transitions from exon I to exon III and from exon III to the exon V of the GpA gene. This mRNA lacked both exons II and VI, resulting in the deletion of 46 amino acids. Is is concluded that these truncated mRNAs are transcribed from the same gene as the GpA gene and correspond to splicing isoforms lacking different exons.
Nine salivary polymorphic systems (Pa, Pb, Pr, Db, PmF, PIF, Ph, Amy1 and s-AcP) were examined using parotid and whole saliva from random Japanese individuals. The gene frequencies obtained were: Pa+ = 0.221, Pb1 = 1.000 Pr1 = 0.741, Db+ = 0.033, PIF+ = 0.715, Ph+ = 0.029, Amyv1 = 0.013 and s-AcPA = 0.217, respectively.
In 332 samples of human parotid saliva collected at random from a Japanese population, the genetic polymorphism of salivary alpha-amylase was detected by isoelectric focusing electrophoresis in a pH range of 5.2-7.2 polyacrylamide gel followed by silver staining. This polymorphism, that was tentatively designated Amy1 S, consisted of extra three isozymes of a normal pattern (Amy1 N) and isoelectric points of these three isozymes were 5.5, 5.8 and 6.1, respectively. The inheritance was controlled by a dominant allele at an autosomal locus. The frequency of the genes determining these phenotypes were studied as follows: Amy1 S = 0.014 +/- 0.004, Amy1 N = 0.986 +/- 0.004.
Magnetic resonance (MR) characteristics of metastatic brain tumors (MBTs) were studied using 15 cases (13 males and 2 females whose ages ranged from 32-78 yr, with the mean age of 57.8 yr; 12 adenocarcinomas, 2 squamous-cell carcinomas, 2 large-cell carcinomas). Nine cases showed hypointensities and five showed isointensities on T1-weighted images. Six cases showed markedly hypo- or hypointensities, two showed isointensities, and six showed markedly hyper- or hyperintensities on T2-weighted images. One case was markedly hyperintense on both T1- and T2-weighted images. The decrease of the signal intensity on the T2-weighted image was the main MR characteristic. A hypointense peritumoral rim was seen in four of the six hyperintense tumors on T2-weighted images. There was no correlation between the signal intensity and the histological classification.
MR findings of five posterior fossa hemangioblastomas were reported. In the cystic type, a cyst was low intensity on T1WI and high intensity on T2WI. Mural nodule was clearly enhanced by Gd-DTPA. In the solid type, the tumor was shown as an isointense lesion on T1WI and as high intensity on T2WI, but it was markedly and homogeneously enhanced by Gd-DTPA. Multiple extremely low-intensity serpentine "flow void" signs, indicating afferent and efferent vessels, were observed within or around the tumor. These were characteristic pictures in this tumor.
The magnetic resonance signal intensity and cyst content were analyzed in 2 new and 17 previously reported cases of Rathke cleft cyst. Lesions displaying hypointensity on T1-weighted images (T1WI) and hyperintensity on T2-weighted images (T2WI) contained CSF-like fluid. Cases showing hyperintensity on T1WI and isointensity on T2WI frequently contained mucoid material. Hyperintensity on both T1WI and T2WI suggests the presence of blood. A small area of hypo- or isointensity indicates thickening of the cyst wall or collection of cellular debris.
A guanine-adenine substitution was observed in exon 5 of the human transferrin (TF) gene. The nucleotide change led to an AvaI digestion site. Analysis of the segregation of the AvaI polymorphism and serum TF phenotypes indicated that an intragenic recombination occurred between the AvaI polymorphic site and the mutation site in the TF gene which determines the two common TF alleles, TF*C1 and TF*C2.
BACKGROUND: To investigate the mechanisms of cisplatin (CDDP)-resistance in neuroblastoma(NB), we established a CDDP-resistant human NB cell line, BM1R2. MATERIALS AND METHODS: We characterized BM1R2 in terms of the susceptibilities to other anticancer agents, MDR1 and MRP expression, MYCN amplification, intracellular gultathione-S-transferase(GST-pi), metallothionein(MT) and gultathione(GSH) levels, and immunocytochemical and cytogenetic features. RESULTS: When compared to parent BM1 line, BM1R2 exhibited a 17.0-fold resistance to CDDP and cross-resistance to other agents. MRP expression was only observed in BM1R2, whereas MDR1 was expressed in both lines. Notably higher intracellular GST-pi and MT levels were observed in BM1R2 cells. MYCN amplifications were 50 and 6 copies in BM1 and BM1R2, respectively, and additional aberrations were observed in chromosome 1 and 2 in BM1R2. CONCLUSION: It was suggested that GST-pi and MT could exert crucial roles on CDDP-resistance in our system. BM1R2 is of great interest for investigating the mechanisms of CDDP-resistance in NB.
A genetic study was carried out on phenotype and gene frequencies of the genetic markers in four red cell enzymes, acid phosphatase (ACP1), esterase D (ESD), 6-phosphogluconate dehydrogenase (PGD) and phosphoglucomutase 1 (PGM1) among the Japanese population living on Izena Island of Okinawa Prefecture. The gene frequencies obtained were ACP1*A = 0.284, ACP1*B = 0.716, ESD*1 = 0.436, ESD*2 = 0.564, PGD*A = 0.947, PGD*C = 0.053, PGM1*1- = 0.112, PGM1*1+ = 0.602, PGM1*2- = 0.161, PGM1*2+ = 0.125. The population living on Izena Island is characterized by higher ACP1*A and PGM1*2 gene frequencies than those of Tokyo population.
As of January 1986, 13 patients with adenocarcinoma of the prostate had been treated in our clinic by remote after-loading transurethral high dose rate radiotherapy using a 60Co source. Of these patients, four were at stage B2, three at stage C, three at stage D1, and three at stage D2. The mean total dose of transurethral radiotherapy was 35.2 Gy to the most distant prostatic capsule from the source. Three patients with stage D1 disease and one patient with stage C disease received additional external radiation with a total dose of 20 Gy to the prostate and 40 Gy to the pelvis. Local tumor response proved rapid and satisfactory as verified by rectal examination, ultrasonography, and needle biopsy. Serious complications such as proctitis, cystitis, incontinence, and urethral stricture were not evident during the average follow-up term of 34.9 months.
Magnetic resonance (MR) imaging of pituitary adenoma is usually carried out in dynamic studies with bolus contrast material injections, with the result that few strong images are obtained. Dynamic studies using a slowly injected contrast material were carried out in 14 cases of pituitary adenomas. The examinations were performed with a 1.5 Tesla superconducting MR imaging system using the spin-echo technique. Gd-DTPA (0.1 mmol/kg) was slowly injected (within 90 sec) by hand, providing seven to nine dynamic images during 350 sec from the start of injection. The average time to reach the maximum signal intensity was 170.6 sec in adenoma and 156.2 sec in normal gland tissue. The maximum contrast signal intensity ratio of adenoma to normal gland was 0.527 in the fifth image. The contrast of adenoma to normal gland tissue was calculated by the following formula: ASII (adenoma signal intensity index) = (adenoma signal intensity-tissue signal intensity)/tissue signal intensity. The most remarkable contrast between adenoma and normal tissue was obtained from the fourth to eighth images. In other words, we could obtain the strongest contrast at 144.8 sec to 299.6 sec from the start of contrast injection. Our results with slow injection suggest that stronger images can be obtained a longer period after contrast injection.